Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.

Slides:



Advertisements
Similar presentations
Synopsis of FDA Colorectal Cancer Endpoints Workshop Michael J. O’Connell, MD Director, Allegheny Cancer Center Associate Chairman, NSABP Pittsburgh, PA.
Advertisements

CRITICAL READING OF THE LITERATURE RELEVANT POINTS: - End points (including the one used for sample size) - Surrogate end points - Quality of the performed.
Clinical Perspective. Screening/Prevention Who is at risk for what type Decision to Intervene: Risk Assessment normal Evidence of Disease Disability Death.
Breast cancer and medical second opinion
Alexander Stein University Cancer Center Hamburg, Germany
Post G.I. ASCO Update: Colorectal Cancer Ronald Burkes, M.D.
Colorectal Cancer Center Jena Introduction In Germany, there are currently approximately newly diagnosed patients with colorectal carcinoma.
Advanced Cancer Topics Journal Review 4/16/2009 AD.
Slides last updated: June 2015 CRC: CLINICAL FEATURES.
The Colorectal Cancer Center Jena Gharbi A, Settmacher U. Department of General, Visceral and Vascular Surgery, Friedrich-Schiller-University Jena
Mizutomo Azuma 1, Dongyun Yang 2, Marinella Carpanu 3, Ellen Hollywood 3, Michael Lue-Yat 3, Wu Zhang 1, Kathleen D. Danenberg 4, Peter V. Danenberg 5,
Treatment should start with Chemotherapy before Surgery:
Mace L. Rothenberg, M.D. Professor of Medicine Ingram Professor of Cancer Research Biomarkers in Colorectal Cancer Management: KRAS Mutations and EGFR.
MABEL – a large multinational study of cetuximab plus irinotecan in metastatic colorectal cancer progressing on irinotecan H Wilke, R Glynne-Jones, J Thaler,
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Patterns of Care in Medical Oncology Treatment of Metastatic Colon Cancer.
Annals of Oncology 23: 298–304, 2012 종양혈액내과 R4 김태영 / prof. 김시영.
Dr. Marco Matos JOURNAL CLUB GCUH 4/07/14.
Presented By Alan Venook at 2016 ASCO Annual Meeting
Managing Colon cancer in the era of molecular markers
RECURRENT METASTATIC LARGE CELL NEUROENDOCRINE CARCINOMA OF CAECUM
CCO Independent Conference Coverage
8th Mucscat International Oncology conference. Muscat, Oman
Prognostic Factors for First-line Chemotherapy + Bevacizumab or Cetuximab in Metastatic Colorectal Cancer CCO Independent Conference Highlights* of the.
Presented By Michael Lee at 2016 ASCO Annual Meeting
Early tumor shrinkage (ETS) and depth of response (DpR) to anti-EGFR in (m)CRC helpful surrogates or meaningless endpoints? Marc Peeters MD, PhD Coordinator.
CUP SSG May 2016 Dr Matt sephton
Fondazione Poliambulanza - Brescia
Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.
COPD by the Guidelines.
Challenges in RAS Wild-Type mCRC
New ESMO Guidance on Tumor Sidedness in mCRC
Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.
A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.
What to Do Next: Sequencing of Therapy in Patients With Metastatic CRC
The Genomics of Cancer and Molecular Testing:
Colorectal Cancer: Current “Standard” Uses for Molecular Testing
The Nurse View: Overcoming Challenges Associated With Cancer Immunotherapy.
The Nurse View: Updates in the Management of Metastatic Colorectal Cancer.
Optimizing Outcomes in the Management of GIST
Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.
A proposed treatment model for the decision-making process when choosing between cetuximab continuation vs rechallenge. aTypically patients with left-sided,
THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES
T790M Mutation-Positive NSCLC: A Multidisciplinary Case Conference
Liquid Biopsy for RAS Screening in CRC: How Can We Successfully Implement This New Paradigm?
Volume 150, Issue 4, Pages (April 2016)
Locally Advanced NSCLC Implementing Innovation
Basics of Immunotherapy Potential Therapeutic Targets.
Managing gBRCA-Positive Metastatic Breast Cancer
Evidence-based Medicine Curriculum
Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.
Published online September 20, 2017 by JAMA Surgery
Challenges in LA SCCHN.
THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES
New Insights on Treatment Strategies for mCRC:
Raymond N. DuBois, M.D., Ph.D. Executive Director
This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.
Ali Shamseddine,MD,FRCP
CRC-TREATMENT BEYOND SECOND LINE
The Nurse View: Spotlight on EGFR-Mutated NSCLC
Investigator Perspectives on the Current Utility of Validated and Emerging Biomarkers to Guide Treatment Decision-Making for Patients with Metastatic Colorectal.
Finding the Right Sequence in Patients With EGFR-Mutated NSCLC
Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.
MSI.
The Nurse View.
General strategies of Cancer Treatment and evaluation of Response
Molecular heterogeneity drives secondary resistance to anti-EGFR therapies in mCRC. Molecular heterogeneity drives secondary resistance to anti-EGFR therapies.
Consort diagram of the study depicting the process of patients’ selection. Consort diagram of the study depicting the process of patients’ selection. A.
Presentation transcript:

TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION

Introduction

Pathological Distinctions Between CRC Tumors

mCRC: Sidedness and Outcomes

Relevance of PTL in mCRC: What Is the Impact on Clinical Decisions?

Case 1: Left-Sided mCRC

Treatment Options for Left-Sided mCRC

Treatment-Related AEs Associated With EGFR Inhibitors

CT ± Cetuximab in Patients With Resectable Colorectal Liver Metastasis: New EPOC Study

ESMO Consensus Guidelines for the Management of Patients With mCRC

NCCN Guidelines for the Treatment of Colon Cancer

Case 2: Right-Sided CRC

PTL in mCRC: Meta-Analysis Findings

EGFR Inhibitor-Associated Dermatologic Toxicities

Molecular Biomarker Testing for the Evaluation of CRC

Transverse CRC: Shared Embryology, Pathology, and Genetics

The Use of Tumor Sidedness as a Potential Surrogate Marker

Concluding Remarks

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.